| Plozasiran for treating familial chylomicronaemia syndrome [ID6593] | Technology appraisal guidance | TBC |
| Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] | Technology appraisal guidance | |
| Polycystic ovary syndrome: assessment and management | NICE guideline | |
| Prostate cancer: diagnosis and management (update) | NICE guideline | TBC |
| Psoriasis: assessment and management (CG153) | NICE guideline | TBC |
| Pulmonary artery pressure technologies for remote monitoring of chronic heart failure | Diagnostics guidance | |
| Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512] | Technology appraisal guidance | |
| Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319] | Technology appraisal guidance | TBC |
| Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
| Remibrutinib for treating chronic spontaneous urticaria
inadequately controlled by H1-antihistamines ID6356 | Technology appraisal guidance | TBC |
| Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
| Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147] | Technology appraisal guidance | TBC |
| Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] | Technology appraisal guidance | TBC |
| Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007 | Technology appraisal guidance | TBC |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
| Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
| Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
| Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | TBC |
| Ruxolitinib for Prurigo Nodularis [ID6571] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [ID6297] | Technology appraisal guidance | TBC |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Technology appraisal guidance | |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
| Seladelpar for previously treated primary biliary cholangitis [ID6429] | Technology appraisal guidance | |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441] | Technology appraisal guidance | |
| Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458] | Technology appraisal guidance | TBC |
| Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Technology appraisal guidance | TBC |
| Sipavibart for preventing COVID 19 [ID6282] | Technology appraisal guidance | TBC |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | TBC |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147] | Technology appraisal guidance | TBC |
| Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Technology appraisal guidance | |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091 | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632 | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | TBC |
| SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |
| Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
| Spesolimab for preventing generalised pustular psoriasis flares [ID6216] | Technology appraisal guidance | TBC |
| Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086] | Technology appraisal guidance | TBC |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Surgical vessel sealing systems (MT798) | Medical technologies guidance | TBC |
| Suspected Cancer: recognition and referral (update) | NICE guideline | |
| Suspected sepsis: recognition, diagnosis and early management | NICE guideline | TBC |
| Suspected sepsis: recognition, diagnosis and early management | NICE guideline | |
| Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568] | Technology appraisal guidance | |